ConductScience.org, home

Paper20404136

Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia.

Long J and 7 others. Blood, 2010. Cited by 75 papers, by iCite.

Cite this record

ConductScience Library. Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. Papers, record 20404136. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20404136

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia.
PubMed
Journal
Blood
PubMed
Year
2010
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
75
iCite
Relative citation ratio, by iCite
1.49
iCite
Revised in PubMed
2022-03-11
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Long JJianting
2Parkin BBrian
3Ouillette PPeter
4Bixby DDale
5Shedden KKerby
6Erba HHarry
7Wang SShaomeng
8Malek SNSami N

Source PubMed

Download CSV of authors

Topics28

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
ApoptosisMajor topic
Drug Resistance, NeoplasmMajor topic
Proto-Oncogene Proteins c-mdm2Major topic
Acute Disease
Adult
Aged
Aged, 80 and over
Cell Cycle Proteins
Cell Line, Tumor
Cells, Cultured
Female
Flow Cytometry
Humans
Imidazoles
Immunoblotting
Indoles
Leukemia, Myeloid
Male
Middle Aged
Nuclear Proteins
Piperazines
Proto-Oncogene Proteins
Reverse Transcriptase Polymerase Chain Reaction
Spiro Compounds
Tumor Cells, Cultured
Tumor Suppressor Protein p53
Young Adult
fms-Like Tyrosine Kinase 3

Source PubMed

Download CSV of topics

Grants6

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
R01 CA136537NCI NIH HHSUnited StatesR01CA136537PubMed and NIHNIH RePORTER
P30 CA046592NCI NIH HHSUnited StatesP30CA046592PubMed and NIHNIH RePORTER
1R01 CA136537-01NCI NIH HHSUnited StatesR01CA136537PubMed and NIHNIH RePORTER
UL1RR024986NCRR NIH HHSUnited StatesUL1RR024986PubMed and NIHNIH RePORTER
5 P30 CA46592NCI NIH HHSUnited StatesP30CA046592PubMed and NIHNIH RePORTER
UL1 RR024986NCRR NIH HHSUnited StatesUL1RR024986PubMed and NIHNIH RePORTER

Download CSV of grants

References49

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
111867746NQO1 stabilizes p53 through a distinct pathway.Proc Natl Acad Sci U S A2002https://conductscience.org/library/papers/11867746PubMed
218521084E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.Oncogene2008https://conductscience.org/library/papers/18521084PubMed
319151774The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia.Leukemia2009https://conductscience.org/library/papers/19151774PubMed
418641120Loss of p53 synthesis in zebrafish tumors with ribosomal protein gene mutations.Proc Natl Acad Sci U S A2008https://conductscience.org/library/papers/18641120PubMed
517971485Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia.Blood2008https://conductscience.org/library/papers/17971485PubMed
617965322Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients.Blood2008https://conductscience.org/library/papers/17965322PubMed
718765522Targeting the MDM2-p53 interaction for cancer therapy.Clin Cancer Res2008https://conductscience.org/library/papers/18765522PubMed
89153396Regulation of p53 stability by Mdm2.Nature1997https://conductscience.org/library/papers/9153396PubMed
916905541MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin.J Biol Chem2006https://conductscience.org/library/papers/16905541PubMed
1012654245Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation.Cell2003https://conductscience.org/library/papers/12654245PubMed
1116213212Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin.Cell2005https://conductscience.org/library/papers/16213212PubMed
1216946709The tumor suppressor protein p53 is required for neurite outgrowth and axon regeneration.EMBO J2006https://conductscience.org/library/papers/16946709PubMed
1311369655FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia.Blood2001https://conductscience.org/library/papers/11369655PubMed
1416014563MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy.Blood2005https://conductscience.org/library/papers/16014563PubMed
1519411846The transcription-independent mitochondrial p53 program is a major contributor to nutlin-induced apoptosis in tumor cells.Cell Cycle2009https://conductscience.org/library/papers/19411846PubMed
1619776744The first 30 years of p53: growing ever more complex.Nat Rev Cancer2009https://conductscience.org/library/papers/19776744PubMed
1716492744Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo.Proc Natl Acad Sci U S A2006https://conductscience.org/library/papers/16492744PubMed
1818548093The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML.Leukemia2008https://conductscience.org/library/papers/18548093PubMed
1919946262Selective FLT3 inhibitor FI-700 neutralizes Mcl-1 and enhances p53-mediated apoptosis in AML cells with activating mutations of FLT3 through Mcl-1/Noxa axis.Leukemia2010https://conductscience.org/library/papers/19946262PubMed
2016439685MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells.Blood2006https://conductscience.org/library/papers/16439685PubMed

See all 49 referencesDownload CSV of references

Cited by59

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 75 citations.

PMIDTitleJournalYearIn PapersSource
41592087Patients with AML with WT TP53 but defective TP53-mediated apoptosis have a dismal survival.JCI Insight2026https://conductscience.org/library/papers/41592087PubMed
39223295Star wars against leukemia: attacking the clones.Leukemia2024https://conductscience.org/library/papers/39223295PubMed
39030997Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies.Cancer Med2024https://conductscience.org/library/papers/39030997PubMed
37951964Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: immune escape mechanisms and current implications for therapy.Mol Cancer2023https://conductscience.org/library/papers/37951964PubMed
37818252Advancements in MDM2 inhibition: Clinical and pre-clinical investigations of combination therapeutic regimens.Saudi Pharm J2023https://conductscience.org/library/papers/37818252PubMed
37156796Optimized spirooxindole-pyrazole hybrids targeting the p53-MDM2 interplay induce apoptosis and synergize with doxorubicin in A549 cells.Sci Rep2023https://conductscience.org/library/papers/37156796PubMed
35141508Mechanical phenotyping reveals unique biomechanical responses in retinoic acid-resistant acute promyelocytic leukemia.iScience2022https://conductscience.org/library/papers/35141508PubMed
34970530Design, Synthesis, Chemical and Biochemical Insights Into Novel Hybrid Spirooxindole-Based p53-MDM2 Inhibitors With Potential Bcl2 Signaling Attenuation.Front Chem2021https://conductscience.org/library/papers/34970530PubMed
34911439Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?Cell Mol Biol Lett2021https://conductscience.org/library/papers/34911439PubMed
32319019Targeting Apoptosis in Acute Myeloid Leukemia: Current Status and Future Directions of BCL-2 Inhibition with Venetoclax and Beyond.Target Oncol2020https://conductscience.org/library/papers/32319019PubMed
31717784Targeting Apoptotic Pathways in Acute Myeloid Leukaemia.Cancers (Basel)2019https://conductscience.org/library/papers/31717784PubMed
31653912Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia.Nat Commun2019https://conductscience.org/library/papers/31653912PubMed
31649884Targeting the GFI1/1B-CoREST Complex in Acute Myeloid Leukemia.Front Oncol2019https://conductscience.org/library/papers/31649884PubMed
31289443MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388).Onco Targets Ther2019https://conductscience.org/library/papers/31289443PubMed
30115703Targeting the MTF2-MDM2 Axis Sensitizes Refractory Acute Myeloid Leukemia to Chemotherapy.Cancer Discov2018https://conductscience.org/library/papers/30115703PubMed
29976747MDM2- and FLT3-inhibitors in the treatment of FLT3-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurin.Haematologica2018https://conductscience.org/library/papers/29976747PubMed
29857559
The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia.
Cancers (Basel)2018https://conductscience.org/library/papers/29857559PubMed
29571049Lanthanide-doped nanoparticles conjugated with an anti-CD33 antibody and a p53-activating peptide for acute myeloid leukemia therapy.Biomaterials2018https://conductscience.org/library/papers/29571049PubMed
29490944Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition.Cancer Res2018https://conductscience.org/library/papers/29490944PubMed
29343974Identification of key pathways and genes in TP53 mutation acute myeloid leukemia: evidence from bioinformatics analysis.Onco Targets Ther2018https://conductscience.org/library/papers/29343974PubMed

See all 59 cited byDownload CSV of cited by

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
FLT32322PubTator's text mininghttps://conductscience.org/library/genes/2322NCBI Gene
MDM24193PubTator's text mininghttps://conductscience.org/library/genes/4193NCBI Gene
MDM44194PubTator's text mininghttps://conductscience.org/library/genes/4194NCBI Gene
TP537157PubTator's text mininghttps://conductscience.org/library/genes/7157NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/20404136

GET https://conductscience.org/api/papers/v1/20404136/references?page=2